Vaccines targeting tumour angiogenesis—a novel strategy for cancer immunotherapy
- 1 May 2006
- journal article
- review article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 32 (4) , 363-370
- https://doi.org/10.1016/j.ejso.2006.01.016
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- T cell–mediated suppression of angiogenesis results in tumor protective immunityBlood, 2005
- Phase I Study of Immunization with Dendritic Cells Modified with Fowlpox Encoding Carcinoembryonic Antigen and Costimulatory MoleculesClinical Cancer Research, 2005
- The epidermal growth factor receptor as a target for colorectal cancer therapySeminars in Oncology, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Cancer without diseaseNature, 2004
- Inhibition of Tumor Growth with a Vaccine Based on Xenogeneic Homologous Fibroblast Growth Factor Receptor-1 in MiceJournal of Biological Chemistry, 2003
- Validating survivin as a cancer therapeutic targetNature Reviews Cancer, 2003
- Angiogenesis and metastasisEuropean Journal Of Cancer, 1996
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971